<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29795283</article-id><article-id pub-id-type="pmc">5966409</article-id><article-id pub-id-type="publisher-id">26388</article-id><article-id pub-id-type="doi">10.1038/s41598-018-26388-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Positive effects of hydrogen-water bathing in patients of psoriasis and parapsoriasis en plaques</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhu</surname><given-names>Qinyuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wu</surname><given-names>Yueshen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yongmei</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Zihua</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Lanting</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Xiong</surname><given-names>Hao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dai</surname><given-names>Erhong</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Jianhua</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Fan</surname><given-names>Bin</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Ping</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Luo</surname><given-names>Xiaoqun</given-names></name><address><email>luoxiaoqun913@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Department of Dermatology, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Rd., Jing&#x02019;an District, Shanghai, China </aff><aff id="Aff2"><label>2</label>Department of Dermatology, Huadong Hospital, Fudan University, 221 West Yan-an Rd., Jing&#x02019;an District, Shanghai, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2372 7462</institution-id><institution-id institution-id-type="GRID">grid.412540.6</institution-id><institution>Department of Dermatology, </institution><institution>Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725 South Wanping Road, Xuhui District, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.410606.5</institution-id><institution>Department of Dermatology, </institution><institution>Shanghai Dermatology Hospital, 200 Wuyi Road, Chang-ning District, </institution></institution-wrap>Shanghai, China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0369 1660</institution-id><institution-id institution-id-type="GRID">grid.73113.37</institution-id><institution>Department of Dermatology, Changhai Hospital, </institution><institution>The Second Military Medical University, </institution></institution-wrap>168 Changhai Rd., Shanghai, China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2372 7462</institution-id><institution-id institution-id-type="GRID">grid.412540.6</institution-id><institution>Department of Dermatology, </institution><institution>Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, </institution></institution-wrap>110 Ganhe Road, Shanghai, China </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>8</volume><elocation-id>8051</elocation-id><history><date date-type="received"><day>25</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>9</day><month>5</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Psoriasis and parapsoriasis en plaques are chronic inflammatory skin diseases, both representing therapeutic challenge in daily practice and adversely affecting the quality of life. Reactive oxygen species (ROS) has been evidenced to be involved in the pathogenesis of the chronic inflammatory diseases. We now report that hydrogen water, an effective ROS scavenger, has significant and rapid improvement in disease severity and quality of life for patients with psoriasis and parapsoriasis en plaques. At week 8, our parallel-controlled trial revealed 24.4% of patients (10/41) receiving hydrogen-water bathing achieved at least 75% improvement in Psoriasis Area Severity Index (PASI) score compared with 2.9% of patients (1/34) of the control group (<italic>Pc</italic>&#x02009;=&#x02009;0.022, OR&#x02009;=&#x02009;0.094, 95%CI&#x02009;=&#x02009;[0.011, 0.777]). Of patients, 56.1% (23/41) who received bathing achieved at least 50% improvement in PASI score compared with only 17.7%(6/34) of the control group (<italic>P</italic>&#x02009;=&#x02009;0.001, OR&#x02009;=&#x02009;0.168, 95%CI&#x02009;=&#x02009;[0.057, 0.492]). The significant improvement of pruritus was also observed (<italic>P</italic>&#x02009;=&#x02009;3.94&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;4</sup>). Besides, complete response was observed in 33.3% of patients (2/6) of parapsoriasis en plaques and partial response in 66.7% (4/6) at week 8. Our findings suggested that hydrogen-water bathing therapy could fulfill the unmet need for these chronic inflammatory skin diseases.</p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Psoriasis and parapsoriasis en plaques are both chronic inflammatory skin diseases characterized by persistently scaling and inflammatory eruptions<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. They represent therapeutic challenge in daily practice and adversely affect the quality of life of patients<sup><xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref></sup>. Psoriasis is so common that has been recognized since ancient times, affecting about 1% to 3% of the general population<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. It is associated with a high degree of morbidity. Indeed, disability and impact on quality of life secondary to psoriasis parallels that of heart disease and arthritis<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup>. Parapsoriasis en plaques is a relatively rare group of disorders which has been classified into small plaque parapsoriasis (SPP) and large plaque parapsoriasis (LPP) according to the size of the lesions. Although the relation of SPP with mycosis fungoides (MF) is still a matter of discussion, there are about 10&#x02013;30% of cases of LPP result in MF finally<sup><xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref></sup>. The interactive network of the immune system and skin cells is thought to play a vital role in the pathogenesis of both diseases. To be more accurate, psoriasis is considered a Th1&#x02044;Th17-driven disease<sup><xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref></sup>, while parapsoriasis en plaques is a model of cutaneous T cell lympho-proliferative disorders and has been proved to be a monoclonal disorder in many cases. For a long period, conventional treatment to both diseases has not fully met the needs of patients while having well-known side-effects. The improved understanding of the autoimmune inflammatory pathways and associated changing concepts in pathogenesis have led to the development of biological drugs, which especially revolutionized the treatment of psoriasis<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR14">14</xref></sup>. However, slow onset of action, high cost, efficacy lost over time and the long-term safety profile of these biologics still remain unsolved<sup><xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par3">Recently, it has been evidenced that oxidative stress such as increased reactive oxygen species (ROS) production may be involved in the pathogenesis of chronic inflammatory diseases<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. The possibility of using this information to develop novel strategies for treatment is of considerable interest. Hydrogen molecule (H<sub>2</sub>) has been used in medical applications as a safe and effective antioxidant and immunomodulator with minimal side effects<sup><xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref></sup>. Unlike other antioxidants, which are unable to target organelles, H<sub>2</sub> can penetrate biomembranes and diffuse into the cytosol, mitochondria and nucleus<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Moreover, it has also been reported to selectively scavenge ROS<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> and show positive influence in Th1, Th2, and pro-inflammatory cytokine imbalance<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Up to date, hydrogen water (solubilized H<sub>2</sub>) as a treatment strategy for psoriasis-associated skin lesions has been tried by few case reports<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>, and neither has hydrogen water for patients with parapsoriasis en plaques. Apart from drinking hydrogen water, inhalation of hydrogen gas and injecting H<sub>2</sub>-dissolved saline, hydrogen-water bathing is a new approach highlights by its skin-directed, safe and painless administration. Thus, our study conducted a parallel-controlled trial in patients with psoriasis and a self-controlled trial in patients with parapsoriasis en plaques to evaluate the efficacy of hydrogen-water bathing to these chronic inflammatory skin diseases.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Improvement of psoriasis</title><p id="Par4">In all, 41 psoriasis patients were assigned to treatment with hydrogen-water bathing therapy and 34 patients were assigned to the control group. The treatment groups were well balanced with respect to demographics and baseline characteristics (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Only one patient of the control group withdrew during the course of the study at week 2 due to a lack of improvement and she was counted as a non-responder in the control group. Response was evident after 8-week bathing therapy. The mean Psoriasis Area Severity Index (PASI) score and median visual analog scale (VAS) score of the hydrogen-water bathing group at week 8 was 5.8 and 0 respectively, significantly lower than the baseline scores (<italic>P</italic>&#x02009;=&#x02009;7.08&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup>; <italic>P</italic>&#x02009;=&#x02009;2.42&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5</sup>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of the psoriasis patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">The Hydrogen-water bathing group</th><th colspan="2">The control group</th></tr><tr><th>Baseline</th><th>Week 8</th><th>Baseline</th><th>Week 8</th></tr></thead><tbody><tr><td>No</td><td>41</td><td>41</td><td>34</td><td>33</td></tr><tr><td>Sex(male/female)</td><td>24/17</td><td>24/17</td><td>18/16</td><td>18/15</td></tr><tr><td>Age</td><td>40&#x02009;&#x000b1;&#x02009;15 (18&#x02013;78)</td><td>40&#x02009;&#x000b1;&#x02009;15 (18&#x02013;78)</td><td>39&#x02009;&#x000b1;&#x02009;12 (18&#x02013;72)</td><td>39&#x02009;&#x000b1;&#x02009;13 (18&#x02013;72)</td></tr><tr><td>BMI</td><td>23.8&#x02009;&#x000b1;&#x02009;3.8 (17.5&#x02013;35.5)</td><td>23.7&#x02009;&#x000b1;&#x02009;3.9 (17.2&#x02013;35.6)</td><td>23.1&#x02009;&#x000b1;&#x02009;4.2 (15.5&#x02013;31.4)</td><td>23.0&#x02009;&#x000b1;&#x02009;4.6 (15.3&#x02013;31.4)</td></tr><tr><td>Waistline (cm)</td><td>82.7&#x02009;&#x000b1;&#x02009;10.3 (63.3&#x02013;103.3)</td><td>82.8&#x02009;&#x000b1;&#x02009;9.8 (63.3&#x02013;103.3)</td><td>76.8&#x02009;&#x000b1;&#x02009;8.7 (58.2&#x02013;95.4)</td><td>76.8&#x02009;&#x000b1;&#x02009;8.9 (58.2&#x02013;95.4)</td></tr><tr><td>PASI score</td><td>9.8&#x02009;&#x000b1;&#x02009;5.9 (1.4&#x02013;25.2)</td><td>5.8&#x02009;&#x000b1;&#x02009;5.5 (0.2&#x02013;25.2)</td><td>8.5&#x02009;&#x000b1;&#x02009;4.1 (2.8&#x02013;23.8)</td><td>7.9&#x02009;&#x000b1;&#x02009;6.8 (0.8&#x02013;34.5)</td></tr><tr><td>VAS score (median, range)</td><td>2 (0&#x02013;8)</td><td>0 (0&#x02013;4)</td><td>0 (0&#x02013;7)</td><td>0 (0&#x02013;9)</td></tr></tbody></table><table-wrap-foot><p>PASI: Psoriasis Area Severity Index; VAS: the visual analog scale; BMI: Body Mass Index.</p></table-wrap-foot></table-wrap></p><p id="Par5">After 8 weeks of therapy, patients treated with hydrogen-water bathing showed significantly greater improvement than those who were of the control group as evaluated by both PASI and VAS (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Of patients, 24.4% receiving hydrogen-water bathing achieved the end point of at least 75% improvement in PASI score compared with 2.9% of patients of the control group (<italic>Pc</italic>&#x02009;=&#x02009;0.022, OR&#x02009;=&#x02009;0.094, 95%CI&#x02009;=&#x02009;[0.011, 0.777]). Of patients, 56.1% who received bathing achieved at least 50% improvement in PASI compared with only 17.7% of the control group (<italic>P</italic>&#x02009;=&#x02009;0.001, OR&#x02009;=&#x02009;0.168, 95%CI&#x02009;=&#x02009;[0.057, 0.492]). Hydrogen-water bathing treatment also resulted in substantial improvement in pruritus as measured by VAS. The median change from baseline to week 8 in the bathing group was &#x02212;2, compared with a median change of 0 in the control group (<italic>P</italic>&#x02009;=&#x02009;3.94&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;4</sup>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Summary of the improvement of Psoriasis Area and Severity Index (PASI) and visual analog scale (VAS) at week 8.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="4" colspan="2"/><th colspan="4">The Hydrogen-water bathing group</th><th colspan="4">The control group</th><th rowspan="4"><italic>P</italic> value</th></tr><tr><th colspan="4">Baseline PASI score</th><th colspan="4">Baseline PASI score</th></tr><tr><th>Mild</th><th>Moderate</th><th>Severe</th><th>Total</th><th>Mild</th><th>Moderate</th><th>Severe</th><th>Total</th></tr><tr><th>(N&#x02009;=&#x02009;26)</th><th>(N&#x02009;=&#x02009;11)</th><th>(N&#x02009;=&#x02009;4)</th><th>(N&#x02009;=&#x02009;41)</th><th>(N&#x02009;=&#x02009;24)</th><th>(N&#x02009;=&#x02009;9)</th><th>(N&#x02009;=&#x02009;1)</th><th>(N&#x02009;=&#x02009;34)</th></tr></thead><tbody><tr><td rowspan="3">PASI (%)</td><td>&#x0003e;PASI90</td><td>1 (2.4)</td><td>1 (2.4)</td><td>0</td><td>2 (4.8)</td><td>0</td><td>0</td><td>0</td><td>0</td><td>&#x0003e;0.05</td></tr><tr><td>&#x0003e;PASI75</td><td>5 (12.2)</td><td>3 (7.3)</td><td>2 (4.9)</td><td>10 (24.4)</td><td>1 (2.9)</td><td>0</td><td>0</td><td>1 (2.9)</td><td>0.022<sup>*</sup></td></tr><tr><td>&#x0003e;PASI50</td><td>13 (31.7)</td><td>8 (19.5)</td><td>2 (4.9)</td><td>23 (56.1)</td><td>4 (11.8)</td><td>2 (5.9)</td><td>0</td><td>6 (17.6)</td><td>0.001</td></tr><tr><td rowspan="4">VAS improvement (%)</td><td>&#x02264;&#x02212;5</td><td>3 (7.3)</td><td/><td/><td/><td>0 (0)</td><td/><td/><td/><td>0.31<sup>*</sup></td></tr><tr><td>&#x02264;&#x02212;3</td><td>9 (22.0)</td><td/><td/><td/><td>1 (2.9)</td><td/><td/><td/><td>0.04<sup>*</sup></td></tr><tr><td>&#x0003c;0</td><td>21 (51.2)</td><td/><td/><td/><td>7 (20.6)</td><td/><td/><td/><td>0.006</td></tr><tr><td>&#x02265;0</td><td>20 (48.8)</td><td/><td/><td/><td>27 (79.4)</td><td/><td/><td/><td>0.006</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup>The corrected <italic>P</italic> (<italic>P</italic>c) values were adjusted by using Yate&#x02019;s correction for continuity.</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Figure 1</label><caption><p>Clinical improvement of psoriasis of an 8-week course of hydrogen-water bathing therapy. <bold>Case 1:</bold> A 64-year-old psoriasis patient at baseline (PASI 16.4, <bold>a</bold>,<bold>b</bold>) and after the bathing therapy (PASI 1.8, <bold>c</bold>,<bold>d</bold>). Although he had been treated with acitretin capsules 30&#x02009;mg daily for more than 4 months, the psoriatic lesions had not improved except for the partially reduced scale on the plaque. He refused to increase the drug dose due to intolerable dryness and chapping of the mucous membranes. <bold>Case 2</bold>: A 40-year-old psoriasis patient at baseline (PASI 21.1, <bold>a,b</bold>) and after the last bathing therapy (PASI 4.1, <bold>c</bold>,<bold>d</bold>). He complained of severely itching and treatment-resistant lesions (acitretin capsules 40&#x02009;mg daily for more than 6 months), and after bathing therapy he was able to reduce the dose. <bold>Case 3</bold>: A 43-year-old psoriasis patient at baseline (PASI 20.2, <bold>a</bold>,<bold>b</bold>) and after the last bathing therapy (PASI 4.8, <bold>c</bold>,<bold>d</bold>). This man had been continuously treated with methotrexate 5&#x02009;mg weekly for more than 10 months and was able to reduce the dose successfully after bathing therapy. Note that patients experienced similar responses in the areas not shown.</p></caption><graphic xlink:href="41598_2018_26388_Fig1_HTML" id="d29e946"/></fig></p></sec><sec id="Sec4"><title>Improvement of parapsoriasis en plaques</title><p id="Par6">Six patients were included: 1 man and 5 women, with mean age of 32.8&#x02009;&#x000b1;&#x02009;4.9 (range: 25&#x02013;40) years and mean course duration of 34.4&#x02009;&#x000b1;&#x02009;31.1 (range: 12&#x02013;96) months. Four patients were categorized as LPP and two as SPP. Features of the patients were presented in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. In all patients, an improvement in the morphology or distribution of lesions had occurred (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Complete response was observed in 33.3% of patients (2/6), partial response in 66.7% (4/6).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Characteristics and the clinical outcomes of patients with parapsoriasis en plaques.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patients</th><th>Sex/Age</th><th>Type of parasporiasis</th><th>Distribution at initial presentation</th><th>Morphology at initial presentation</th><th>Duration of disease (month)</th><th>Clinical response at week 8</th></tr></thead><tbody><tr><td>1</td><td>F/40</td><td>LPP</td><td>trunk and extremities</td><td>patch, plaque</td><td>25</td><td>PR</td></tr><tr><td>2</td><td>F/31</td><td>LPP</td><td>trunk</td><td>papule, patch</td><td>12</td><td>PR</td></tr><tr><td>3</td><td>F/33</td><td>SPP</td><td>trunk and extremities</td><td>papule, patch, plaque</td><td>28</td><td>PR</td></tr><tr><td>4</td><td>F/33</td><td>SPP</td><td>trunk</td><td>papule, patch</td><td>15</td><td>PR</td></tr><tr><td>5</td><td>M/35</td><td>LPP</td><td>trunk and extremities</td><td>patch, plaque</td><td>30</td><td>CR</td></tr><tr><td>6</td><td>F/25</td><td>LPP</td><td>trunk and extremities</td><td>patch, plaque</td><td>96</td><td>CR</td></tr></tbody></table><table-wrap-foot><p>SPP: small plaque parapsoriasis; LPP: large plaque parapsoriasis; PR: partial response; CR: complete response.</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Figure 2</label><caption><p>Clinical evaluation of a patient of parapsoriasis en plaques who achieved complete response rapidly 4 weeks after hydrogen-water bathing. A 35-year-old man with large plaque parapsoriasis had been followed up for 30 months and during that time two biopsies were taken showing no progression. He had suffered flare-up after 10-month narrow-band UVB therapy and failed to have evident improvement in the later 6-month phototherapy despite of increasing the power. Even if only 4 weeks, his lesions rapidly achieved significant improvements without concomitant therapy (<bold>a</bold>). The Hematoxylin-eosin stain shows mildly hyperkeratotic and focally parakeratotic epidermis with moderately dense superficial perivascular infiltrate. Lymphoid cells are mostly small, cytologically normal lymphocytes, and there is focal single-cell epidermotropism (<bold>b</bold>).</p></caption><graphic xlink:href="41598_2018_26388_Fig2_HTML" id="d29e1146"/></fig></p></sec><sec id="Sec5"><title>Adverse events</title><p id="Par7">Two psoriasis patients complained of the temperature of the hydrogen water. The discomfort was relieved once the actual temperature was adjusted according to the satisfaction of patients. No other adverse reactions were found during the study.</p></sec></sec><sec id="Sec6" sec-type="discussion"><title>Discussion</title><p id="Par8">The results of the parallel-controlled trial demonstrated that hydrogen-water bathing therapy led to significant improvements in psoriasis for the majority of patients. The response rate observed was obviously higher than those seen with Alefacept and fumaric acid esters; and was similar to those seen with Efalizumab, low dose of oral methotrexate (MTX) (5&#x02013;15&#x02009;mg/week) and cyclosporine A (1.25&#x02009;mg/kg/day)<sup><xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref></sup>. Furthermore, patients receiving hydrogen-water bathing showed rapid onset of improvement from baseline. Approximately one forth of patients showed at least 75% improvement in PASI score 8 weeks after their initial bath, a level of response that has only been observed after 12 or more weeks of therapy in patients receiving some biologic agents<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>. Patients treated with hydrogen-water bathing also showed substantial improvement in pruritus as assessed by VAS. This is beneficial to the quality of life of psoriasis, which is considered to be similar to, if not worse than, that of other major chronic diseases. Although concomitant treatment was used for the skin lesions, it should be noted that the dosage of MTX, UVB phototherapy and systemic retinoids concomitantly used were not effective for at least 4 months prior to participation in the present study. Surprisingly, 6 patients were able to reduce or even stop the drug dosage (4 patients: acitretin; 2 patients: MTX) after the bathing course. Although the possibility that the improvements were caused by concomitant treatment cannot be fully excluded, it is indicated that the quick relief of symptom was in great part owing to the bathing therapy.</p><p id="Par9">To parapsoriasis en plaques, our result suggested that hydrogen-water bathing was rapidly effective and safe for the control of the disease with 66.7% partial response and 33.3% complete response. Currently, PUVA and narrow-band UVB are used as main treatment options for parapsoriasis en plaques with up to 80% complete remission rates and a median time to clearance of 2&#x02013;6 months<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup>. In general, UVB is preferred in patients with patches and thin plaques and PUVA photochemotherapy should be used for patients with thick plaques, with phototypes &#x02265;III and unresponsive to UVB<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. However, in addition to requirement of long time to induce the response and the maintenance, all these therapies are associated with potential risk of photocarcinogenesis and photoaging limits their long-term use.</p><p id="Par10">Psoriasis and parapsoriasis en plaques are known as representative diseases that show the orchestrated mechanisms of chronic inflammation. The clinical effectiveness of hydrogen-water may partially be explained by H<sub>2</sub> selectively scavenger ability against highly active oxidants, such as hydroxyl radical and peroxynitrite, and cytoprotective effects against oxidative stress<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Hydroxyl radical is known as a major trigger of the chain reaction of free radicals<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>, and the absence of the specific scavenger of this species spontaneously causes oxidative states in chronic inflammation<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup>. Thus, H<sub>2</sub> may have an advantage to suppress the chain reaction, which produces lipid peroxide and leads to the generation of oxidative stress markers, such as malondialdehyde (MDA)<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> which has been proved to be in association with the exacerbation of psoriasis<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Another target of H<sub>2</sub>, peroxynitrite, which is generated from the reaction of nitric oxide with superoxide, activates <italic>p</italic>38 MAPK pathways which are related to production of inflammatory cytokines, such as TNF-&#x003b1;,IL-6, IL-8 and many others<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>, resulting in the development of plaque of psoriasis<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. Subsequent studies indicate that the effect of H<sub>2</sub> is mediated by Nrf2-Keap1 system<sup><xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>, a transcriptional factor known to be an activator of intrinsic protective mechanisms against oxidative stress, but the mechanisms remain to be solved. However, radical scavenging effects of H<sub>2</sub> cannot fully explain the anti-inflammatory and anti-apoptotic effects, which should involve a number of fine-tuned signaling pathways. Studies also have shown that H<sub>2</sub> suppresses signaling pathways in allergies<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> and inflammation<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> without directly scavenging reactive oxygen/nitrogen species.</p><p id="Par11">In fact, anti-oxidant therapies to psoriasis have already been tested, e.g. using fumaric acid esters particularly in Germany<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. However, most of them exhibited limited therapeutic success. Furthermore, recent studies suggested that some ROS act as signaling messengers to regulate a wide variety of physiological process<sup><xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR41">41</xref></sup>. In view of this background, an ideal antioxidant is expected to mitigate excess oxidative stress, but not disturb redox homeostasis. H<sub>2</sub> has the capability to scavenge specifically potent ROS but does not react with those that have important physiological roles<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. The safety of H<sub>2</sub> is also established by its intrinsic production in the human body and inertness against biogenic components. It has been already used for the prevention of decompression sickness in deep divers<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. The clinical practice of H<sub>2</sub> in the treatment of chronic inflammatory disease was recently attempted in patients of rheumatoid arthritis (RA)<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Moreover, a latest case report suggested H<sub>2</sub> could relieve psoriasis-associated skin lesions and arthritis<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Apart from other methods of application, hydrogen-water bathing is a new approach highlights by its skin-directed, safe and painless administration and can be carried out in daily life.</p><p id="Par12">Regarding the present study, our results showed a decreased trend of BMI in psoriasis patients treated with bathing therapy without any lipid-lowering interventions. This result matches those of previous studies, which have demonstrated the clinical improvement in patients with psoriasis was associated with a reduction in the levels of lipid peroxidation and an increased serum antioxidant capacity<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. In addition, it should be noted that the itching sensation was markedly reduced in most cases. The influence of hydrogen water on itching sensation suggests the presence of neurogenic inflammation associated with ROS in the psoriatic lesion and the possibility of a therapeutic approach similar to that for neurological inflammatory disorders<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Some limitations of this study need to be pointed out. As an open trial of limited sample size, this study may include selection bias although the baseline characteristics of the psoriasis groups including primary PASI and VAS scores showed well balanced. Attention should be paid that the patients receiving hydrogen-bathing therapy are those who have failed to conventional treatment for more than 4 months. This at least implied the disease activities of these &#x0201c;refractory&#x0201d; patients were in less stable condition. Secondly, this study did not involve a placebo control group owing to the ethics concern. However, all the ones of the control group had received tap-water bathing more than twice a week during this study. Thus, the control group of psoriasis was administered with the combination therapy of the conventional therapy and the placebo (tap-water) bathing.</p><p id="Par13">In summary, patients with psoriasis and parapsoriasis en plaques who were treated with hydrogen-water bathing therapy achieved significant and rapid improvement in disease severity and quality of life. We suggested that hydrogen-water bathing therapy could fulfill the unmet need for an alternative therapeutic option for these patients. Further large randomized placebo-controlled trials are required to verify and extend these results. The mechanism and long-term efficacy of hydrogen-water in these diseases are also warranted.</p></sec><sec id="Sec7" sec-type="materials|methods"><title>Methods</title><sec id="Sec8"><title>Patients</title><p id="Par14">Forty-one patients of psoriasis and six patients of parapsoriasis en plaques were enrolled from February 2016 to April 2017 from Huashan Hospital affiliated to Fudan University and Huadong Hospital affiliated to Fudan University. The control group of psoriasis included thirty-four patients recruited from the dermatology clinics of Huashan Hospital. The study was registered and approved by China Ethics Committee of Registering Clinical Trials (ChiCTR-ONC-17013055, 2017/10/20). All patients signed an informed consent form and agreed to publish identifying information or images. All methods were performed in accordance with the relevant guidelines and regulation.</p><p id="Par15">Patients of psoriasis had a history of plaque psoriasis for a minimum of 12 months. Among them, 21 patients were resistant to topical corticosteroid and calcipotriol ointments; the rest of patients suffered conventional treatment failure or failed to reduce the existing dosage of drugs beyond topical corticosteroid and calcipotriol ointments for more than 4 months. The failed therapeutic options include UVB phototherapy (10/41), MTX (3/41), and systemic retinoids (7/41). All the patients declined treatment of other drugs (include biologics) due to financial issues and safety concern. Patients of parapsoriasis en plaques were diagnosed based on clinical, histopathological and immunohistochemical findings (SPP: 2/6, LPP: 4/6). They had been followed up for more than 8 months. Among them, 4 patients had received UVA or narrow-band UVB therapy for more than 6 months without evident improvements. Two patients suffered flare-ups during phototherapy. All biopsies reported dense lymphocytic infiltrates, occasionally with lymphocyte exocytosis. None of the patients had axillary or inguinal lymphadenopathy. The laboratory results of all patients were unremarkable. Patients with serious cardiovascular diseases or infectious diseases, and those who were unable to receive treatment regularly were excluded.</p><p id="Par16">During the duration of hydrogen-water bathing therapy, the present treatments of psoriasis patients were continued the same as before (except for drug tapering), including systemic and topical therapy. The patients of the psoriasis-controlled group were administered the same traditional Chinese patent medicine called &#x0201c;Qu-Yin oral solution&#x0201d;, topical treatment of corticosteroid and calcipotriol ointments. One major ingredient of this widely-used solution is glycyrrhizin, which has been evidenced to enhance the clinical response of psoriasis with its anti-inflammatory and immune-modulating effect<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. All the ones of the control group had received tap-water bathing more than twice a week during this study. Patients of parapsoriasis en plaques did not use any concomitant therapy, except for topical corticosteroid and emollients.</p></sec><sec id="Sec9"><title>Hydrogen water bathing</title><p id="Par17">Hydrogen-water bathing was administrated through skin by immersing whole body in the hydrogen-water twice a week (interval of 3 days). Each bathing took 10 to 15&#x02009;minutes. Hydrogen bathing paused one week in case of menstruation in female subjects. The hydrogen-bathing machine (provided by Shanghai Yiquan Investment Limited Partnership) freshly prepared hydrogen water using nanobubble technology to dissolve hydrogen gas into pure deionized water. In briefly it contained the following process: (1) Tap-water passed through a filtration system (composed of quartz sand, activated carbon, ultrafiltration and reverse osmosis membrane) and an ultraviolet disinfection unit to be deionized and disinfected. (2) Hydrogen generator electrolyzed treated tap-water into oxygen and hydrogen and then collected pure hydrogen gas. (3) Hydrogen gas was forced into micro-nano-level bubbles and the bubbles were then dissolved directly and evenly into deionized water. The freshly prepared hydrogen water had the following physical and chemical characteristics: (1) pH 6.8&#x02013;7.3. (2) Temperature ranged from 38 to 42&#x02009;&#x000b0;C (the actual temperature based on the satisfaction of patients). (3) High content of dissolved hydrogen with a concentration of 1.0 ppm (for reference, the dissolved hydrogen of tap-water is less than 0.001 ppm). (4) With an extremely negative oxidation reduction potential (ORP) of &#x02212;580&#x02009;mV~&#x02009;&#x02212;650&#x02009;mV (for reference, tap water: +250&#x02009;mV~&#x02009;+350&#x02009;mV). Each time before therapy the same equipment was used to test pH, temperature, ORP (RM-30P, DKK-TOA Corp., Japan) and hydrogen concentration (ENH-1000, Trustlex Corp., Japan) to make sure hydrogen water having the same properties.</p></sec><sec id="Sec10"><title>Efficacy evaluation</title><sec id="Sec11"><title>Psoriasis</title><p id="Par18">Clinical assessments including physical examinations, vital signs, concomitant medications, adverse events and measures of psoriasis activity (PASI scores and photos) were estimated at baseline and following each bathing treatment. For the PASI, patients are rated on the basis of erythema, scaling, and thickness divided in four anatomical parts (head, trunk, upper extremities, and lower extremities). The area of each anatomical part is factored into the overall value<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. The score was divided into mild (1&#x02013;10), moderate (10&#x02013;20) and severe (&#x0003e;20) PASI. The PASI score at week 8 was the predefined efficacy endpoint, where a favorable response was an improvement of at least 50% from the baseline PASI<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. The pruritus of the skin lesions was measured by the VAS for itching<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>.</p></sec></sec><sec id="Sec12"><title>Parapsoriasis en plaques</title><p id="Par19">Clinical responses were evaluated at week 8, classified as complete response, &#x0003e;90% clearance of lesions; partial response, 50&#x02013;90% clearance; no response, &#x0003c;50% clearance with persistent skin lesions despite continuing treatment. The pruritus of the skin lesions was measured by VAS as well.</p></sec><sec id="Sec13"><title>Statistical analysis</title><p id="Par20">Analyses of effectiveness endpoints were based on the intent-to-treat (ITT) population. The last-observation-carried-forward (LOCF) analysis was used to estimate the missing data for effectiveness variables. Descriptive variables were summarized by number (percentages), median or mean&#x02009;&#x000b1;&#x02009;standard deviation. Measurement data were compared using paried t-test. Comparison of the count data or level data was performed using &#x003c7;2 tests, Fisher&#x02019;s exact tests or Mann-Whitney U tests. Odds ratio (OR) were calculated with Haldane&#x02019;s modification, which adds 0.5 to all cells to accommodate possible zero counts<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. <italic>P</italic> values were two-tailed. Differences were considered significant at <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05. The corrected <italic>P</italic> (<italic>P</italic>c) values were adjusted by using Yate&#x02019;s correction for continuity. Data were analyzed by SPSS17.0 (SPSS Inc., Chicago, IL, USA) software.</p></sec><sec id="Sec14"><title>Data availability</title><p id="Par21">The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></sec></sec></body><back><fn-group><fn><p>Qinyuan Zhu and Yueshen Wu contributed equally to this work.</p></fn><fn><p><bold>Publisher's note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank Shanghai Yiquan Investment Limited Partnership for the technical support. This study was supported by the HOPE Program launched by the Branch Association of Hydrogen Biomedicine, China-Japan Medical Science and Technology Exchanges Association.</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>Qinyuan Zhu wrote the main manuscript text, analyzed the data and prepared figures. Xiaoqun Luo, Yueshen Wu, Yongmei Li, Erhong Dai, Jianhua Wu and Bin Fan provided follow-up visits to the patients and collected the clinical data. Zihua Chen, Lanting Wang, Hao Xiong and Li Ping contributed to the supervision of regular hydrogen-water bathing therapy. Xiaoqun Luo was in charge of the design and execution of this study. All authors reviewed the manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar1"><title>Competing Interests</title><p id="Par22">The authors declare no competing interests.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nestle</surname><given-names>FO</given-names></name><name><surname>Kaplan</surname><given-names>DH</given-names></name><name><surname>Barker</surname><given-names>J</given-names></name></person-group><article-title>Psoriasis</article-title><source>N Engl J Med.</source><year>2009</year><volume>361</volume><fpage>496</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1056/NEJMra0804595</pub-id><pub-id pub-id-type="pmid">19641206</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sehgal</surname><given-names>VN</given-names></name><name><surname>Srivastava</surname><given-names>G</given-names></name><name><surname>Aggarwal</surname><given-names>AK</given-names></name></person-group><article-title>Parapsoriasis: a complex issue</article-title><source>Skinmed</source><year>2007</year><volume>6</volume><fpage>280</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1111/j.1540-9740.2007.06490.x</pub-id><pub-id pub-id-type="pmid">17975354</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowes</surname><given-names>MA</given-names></name><name><surname>Bowcock</surname><given-names>AM</given-names></name><name><surname>Krueger</surname><given-names>JG</given-names></name></person-group><article-title>Pathogenesis and therapy of psoriasis</article-title><source>Nature</source><year>2007</year><volume>445</volume><fpage>866</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1038/nature05663</pub-id><pub-id pub-id-type="pmid">17314973</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansouri</surname><given-names>Y</given-names></name><name><surname>Goldenberg</surname><given-names>G</given-names></name></person-group><article-title>New systemic therapies for psoriasis</article-title><source>Cutis</source><year>2015</year><volume>95</volume><fpage>155</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">25844781</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson-Huang</surname><given-names>LM</given-names></name><name><surname>Lowes</surname><given-names>MA</given-names></name><name><surname>Krueger</surname><given-names>JG</given-names></name></person-group><article-title>Putting together the psoriasis puzzle: an update on developing targeted therapies</article-title><source>Dis. Model. Mech.</source><year>2012</year><volume>5</volume><fpage>423</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1242/dmm.009092</pub-id><pub-id pub-id-type="pmid">22730473</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aydogan</surname><given-names>K</given-names></name><etal/></person-group><article-title>Efficacy of low-dose ultraviolet a-1 phototherapy for parapsoriasis/early-stage mycosis fungoides</article-title><source>Photochem. Photobiol.</source><year>2014</year><volume>90</volume><fpage>873</fpage><lpage>877</lpage><pub-id pub-id-type="pmid">24502428</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christophers</surname><given-names>E</given-names></name></person-group><article-title>Psoriasis&#x02013;epidemiology and clinical spectrum</article-title><source>Clin. Exp. Dermatol.</source><year>2001</year><volume>26</volume><fpage>314</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2230.2001.00832.x</pub-id><pub-id pub-id-type="pmid">11422182</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapp</surname><given-names>SR</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name><name><surname>Exum</surname><given-names>ML</given-names></name><name><surname>Fleischer</surname><given-names>AB</given-names></name><name><surname>Reboussin</surname><given-names>DM</given-names></name></person-group><article-title>Psoriasis causes as much disability as other major medical diseases</article-title><source>J. Am. Acad. Dermatol.</source><year>1999</year><volume>41</volume><fpage>401</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/S0190-9622(99)70112-X</pub-id><pub-id pub-id-type="pmid">10459113</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Quantifying the harmful effect of psoriasis on health-related quality of life</article-title><source>J. Am. Acad. Dermatol.</source><year>2002</year><volume>47</volume><fpage>512</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1067/mjd.2002.122755</pub-id><pub-id pub-id-type="pmid">12271293</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haeffner</surname><given-names>AC</given-names></name><name><surname>Smoller</surname><given-names>BR</given-names></name><name><surname>Zepter</surname><given-names>K</given-names></name><name><surname>Wood</surname><given-names>GS</given-names></name></person-group><article-title>Differentiation and clonality of lesional lymphocytes in small plaque parapsoriasis</article-title><source>Arch. Dermatol.</source><year>1995</year><volume>131</volume><fpage>321</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1001/archderm.1995.01690150085017</pub-id><pub-id pub-id-type="pmid">7887662</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kikuchi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Parapsoriasis en plaques: its potential for progression to malignant lymphoma</article-title><source>J. Am. Acad. Dermatol.</source><year>1993</year><volume>29</volume><fpage>419</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1016/0190-9622(93)70204-7</pub-id><pub-id pub-id-type="pmid">8394392</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ackerman</surname><given-names>AB</given-names></name></person-group><article-title>If small plaque (digitate) parapsoriasis is a cutaneous T-cell lymphoma, even an &#x02018;abortive&#x02019; one, it must be mycosis fungoides!</article-title><source>Arch. Dermatol.</source><year>1996</year><volume>132</volume><fpage>562</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1001/archderm.1996.03890290096013</pub-id><pub-id pub-id-type="pmid">8624154</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raskin</surname><given-names>CA</given-names></name></person-group><article-title>Small plaque parapsoriasis and mycosis fungoides</article-title><source>Arch. Dermatol.</source><year>1996</year><volume>132</volume><fpage>1388</fpage><pub-id pub-id-type="doi">10.1001/archderm.1996.03890350132026</pub-id><pub-id pub-id-type="pmid">8915323</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinberg</surname><given-names>JM</given-names></name><name><surname>Tutrone</surname><given-names>WD</given-names></name></person-group><article-title>Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept</article-title><source>Cutis.</source><year>2003</year><volume>71</volume><fpage>41</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">12553629</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadam</surname><given-names>DP</given-names></name><name><surname>Suryakar</surname><given-names>AN</given-names></name><name><surname>Ankush</surname><given-names>RD</given-names></name><name><surname>Kadam</surname><given-names>CY</given-names></name><name><surname>Deshpande</surname><given-names>KH</given-names></name></person-group><article-title>Role of oxidative stress in various stages of psoriasis</article-title><source>Indian J. Clin. Biochem.</source><year>2010</year><volume>25</volume><fpage>388</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1007/s12291-010-0043-9</pub-id><pub-id pub-id-type="pmid">21966111</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichihara</surname><given-names>M</given-names></name><name><surname>Sobue</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Hirayama</surname><given-names>M</given-names></name><name><surname>Ohno</surname><given-names>K</given-names></name></person-group><article-title>Beneficial biological effects and the underlying mechanisms of molecular hydrogen - comprehensive review of 321 original articles</article-title><source>Med. Gas. Res.</source><year>2015</year><volume>5</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/s13618-015-0035-1</pub-id><pub-id pub-id-type="pmid">26483953</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohsawa</surname><given-names>I</given-names></name><etal/></person-group><article-title>Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals</article-title><source>Nat. Med.</source><year>2007</year><volume>13</volume><fpage>688</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1038/nm1577</pub-id><pub-id pub-id-type="pmid">17486089</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohta</surname><given-names>S</given-names></name></person-group><article-title>Molecular hydrogen as a novel antioxidant: overview of the advantages of hydrogen for medical applications</article-title><source>Methods Enzymol.</source><year>2015</year><volume>555</volume><fpage>289</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1016/bs.mie.2014.11.038</pub-id><pub-id pub-id-type="pmid">25747486</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohta</surname><given-names>S</given-names></name></person-group><article-title>Recent progress toward hydrogen medicine: potential of molecular hydrogen for preventive and therapeutic applications</article-title><source>Curr. Pharm. Des.</source><year>2011</year><volume>17</volume><fpage>2241</fpage><lpage>2252</lpage><pub-id pub-id-type="doi">10.2174/138161211797052664</pub-id><pub-id pub-id-type="pmid">21736547</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>CS</given-names></name><name><surname>Kawamura</surname><given-names>T</given-names></name><name><surname>Toyoda</surname><given-names>Y</given-names></name><name><surname>Nakao</surname><given-names>A</given-names></name></person-group><article-title>Recent advances in hydrogen research as a therapeutic medical gas</article-title><source>Free Radic. Res.</source><year>2010</year><volume>44</volume><fpage>971</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.3109/10715762.2010.500328</pub-id><pub-id pub-id-type="pmid">20815764</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishibashi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Improvement of psoriasis-associated arthritis and skin lesions by treatment with molecular hydrogen: A report of three cases</article-title><source>Mol. Med. Rep.</source><year>2015</year><volume>12</volume><fpage>2757</fpage><lpage>2764</lpage><pub-id pub-id-type="doi">10.3892/mmr.2015.3707</pub-id><pub-id pub-id-type="pmid">25936373</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brimhall</surname><given-names>AK</given-names></name><name><surname>King</surname><given-names>LN</given-names></name><name><surname>Licciardone</surname><given-names>JC</given-names></name><name><surname>Jacobe</surname><given-names>H</given-names></name><name><surname>Menter</surname><given-names>A</given-names></name></person-group><article-title>Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials</article-title><source>Br. J. Dermatol.</source><year>2008</year><volume>159</volume><fpage>274</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2008.08673.x</pub-id><pub-id pub-id-type="pmid">18547300</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubertret</surname><given-names>L</given-names></name><etal/></person-group><article-title>CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial</article-title><source>Br. J. Dermatol.</source><year>2006</year><volume>155</volume><fpage>170</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2006.07344.x</pub-id><pub-id pub-id-type="pmid">16792770</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>CN</given-names></name><name><surname>Krueger</surname><given-names>GG</given-names></name><name><surname>Group</surname><given-names>ACS</given-names></name></person-group><article-title>Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes</article-title><source>N. Engl. J. Med.</source><year>2001</year><volume>345</volume><fpage>248</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1056/NEJM200107263450403</pub-id><pub-id pub-id-type="pmid">11474662</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>J</given-names></name><etal/></person-group><article-title>Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials</article-title><source>Br. J. Dermatol.</source><year>2014</year><volume>170</volume><fpage>274</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1111/bjd.12663</pub-id><pub-id pub-id-type="pmid">24131260</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fallah</surname><given-names>AS</given-names></name><name><surname>Neumann</surname><given-names>H</given-names></name><name><surname>Hop</surname><given-names>WC</given-names></name><name><surname>Thio</surname><given-names>HB</given-names></name></person-group><article-title>Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial</article-title><source>Br. J. Dermatol.</source><year>2011</year><volume>164</volume><fpage>855</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2010.10195.x</pub-id><pub-id pub-id-type="pmid">21175564</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mease</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial</article-title><source>Lancet.</source><year>2000</year><volume>356</volume><fpage>385</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02530-7</pub-id><pub-id pub-id-type="pmid">10972371</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aydogan</surname><given-names>K</given-names></name><name><surname>Karadogan</surname><given-names>SK</given-names></name><name><surname>Tunali</surname><given-names>S</given-names></name><name><surname>Adim</surname><given-names>SB</given-names></name><name><surname>Ozcelik</surname><given-names>T</given-names></name></person-group><article-title>Narrowband UVB phototherapy for small plaque parapsoriasis</article-title><source>J. Eur. Acad. Dermatol. Venereol.</source><year>2006</year><volume>20</volume><fpage>573</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1111/j.1468-3083.2006.01567.x</pub-id><pub-id pub-id-type="pmid">16684286</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Mofty</surname><given-names>M</given-names></name><etal/></person-group><article-title>Narrow band UVB (311 nm), psoralen UVB (311 nm) and PUVA therapy in the treatment of early-stage mycosis fungoides: a right-left comparative study</article-title><source>Photodermatol. Photoimmunol. Photomed.</source><year>2005</year><volume>21</volume><fpage>281</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0781.2005.00183.x</pub-id><pub-id pub-id-type="pmid">16313238</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niki</surname><given-names>E</given-names></name></person-group><article-title>Lipid peroxidation: physiological levels and dual biological effects</article-title><source>Free Radic. Biol. Med.</source><year>2009</year><volume>47</volume><fpage>469</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2009.05.032</pub-id><pub-id pub-id-type="pmid">19500666</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishibashi</surname><given-names>T</given-names></name></person-group><article-title>Molecular hydrogen: new antioxidant and anti-inflammatory therapy for rheumatoid arthritis and related diseases</article-title><source>Curr. Pharm. Des.</source><year>2013</year><volume>19</volume><fpage>6375</fpage><lpage>6381</lpage><pub-id pub-id-type="doi">10.2174/13816128113199990507</pub-id><pub-id pub-id-type="pmid">23859555</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niki</surname><given-names>E</given-names></name></person-group><article-title>Biomarkers of lipid peroxidation in clinical material</article-title><source>Biochim. Biophys. Acta.</source><year>2014</year><volume>1840</volume><fpage>809</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2013.03.020</pub-id><pub-id pub-id-type="pmid">23541987</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briganti</surname><given-names>S</given-names></name><name><surname>Picardo</surname><given-names>M</given-names></name></person-group><article-title>Antioxidant activity, lipid peroxidation and skin diseases. What&#x02019;s new</article-title><source>J. Eur. Acad. Dermatol. Venereol.</source><year>2003</year><volume>17</volume><fpage>663</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1046/j.1468-3083.2003.00751.x</pub-id><pub-id pub-id-type="pmid">14761133</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>XJ</given-names></name><etal/></person-group><article-title>Expression and localization of the activated mitogen-activated protein kinase in lesional psoriatic skin</article-title><source>Exp. Mol. Pathol.</source><year>2007</year><volume>83</volume><fpage>413</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1016/j.yexmp.2007.05.002</pub-id><pub-id pub-id-type="pmid">17599830</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamura</surname><given-names>T</given-names></name><etal/></person-group><article-title>Hydrogen gas reduces hyperoxic lung injury via the Nrf2 pathway <italic>in vivo</italic></article-title><source>Am. J. Physiol. Lung Cell Mol. Physiol.</source><year>2013</year><volume>304</volume><fpage>L646</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00164.2012</pub-id><pub-id pub-id-type="pmid">23475767</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>X</given-names></name><etal/></person-group><article-title>Lactulose ameliorates cerebral ischemia-reperfusion injury in rats by inducing hydrogen by activating Nrf2 expression</article-title><source>Free Radic. Biol. Med.</source><year>2013</year><volume>65</volume><fpage>731</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2013.08.004</pub-id><pub-id pub-id-type="pmid">23954468</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>T</given-names></name><etal/></person-group><article-title>Molecular hydrogen suppresses FcepsilonRI-mediated signal transduction and prevents degranulation of mast cells</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2009</year><volume>389</volume><fpage>651</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2009.09.047</pub-id><pub-id pub-id-type="pmid">19766097</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>T</given-names></name><etal/></person-group><article-title>Molecular hydrogen inhibits lipopolysaccharide/interferon &#x003b3;-induced nitric oxide production through modulation of signal transduction in macrophages</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2011</year><volume>411</volume><fpage>143</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2011.06.116</pub-id><pub-id pub-id-type="pmid">21723254</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arbiser</surname><given-names>JL</given-names></name></person-group><article-title>Fumarate esters as angiogenesis inhibitors: key to action in psoriasis?</article-title><source>J. Invest. Dermatol.</source><year>2011</year><volume>131</volume><fpage>1189</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1038/jid.2011.45</pub-id><pub-id pub-id-type="pmid">21566578</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Colavitti</surname><given-names>R</given-names></name><name><surname>Rovira</surname><given-names>II</given-names></name><name><surname>Finkel</surname><given-names>T</given-names></name></person-group><article-title>Redox-dependent transcriptional regulation</article-title><source>Circ. Res.</source><year>2005</year><volume>97</volume><fpage>967</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000188210.72062.10</pub-id><pub-id pub-id-type="pmid">16284189</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>EL</given-names></name><name><surname>Klimova</surname><given-names>TA</given-names></name><name><surname>Eisenbart</surname><given-names>J</given-names></name><name><surname>Schumacker</surname><given-names>PT</given-names></name><name><surname>Chandel</surname><given-names>NS</given-names></name></person-group><article-title>Mitochondrial reactive oxygen species trigger hypoxia-inducible factor-dependent extension of the replicative life span during hypoxia</article-title><source>Mol. Cell Biol.</source><year>2007</year><volume>27</volume><fpage>5737</fpage><lpage>5745</lpage><pub-id pub-id-type="doi">10.1128/MCB.02265-06</pub-id><pub-id pub-id-type="pmid">17562866</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohno</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Ichihara</surname><given-names>M</given-names></name></person-group><article-title>Molecular hydrogen as an emerging therapeutic medical gas for neurodegenerative and other diseases</article-title><source>Oxid. Med. Cell Longev.</source><year>2012</year><volume>35</volume><fpage>31</fpage><lpage>52</lpage></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishibashi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Therapeutic efficacy of infused molecular hydrogen in saline on rheumatoid arthritis: a randomized, double-blind, placebo-controlled pilot study</article-title><source>Int. Immunopharmacol.</source><year>2014</year><volume>21</volume><fpage>468</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2014.06.001</pub-id><pub-id pub-id-type="pmid">24929023</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacchetti</surname><given-names>T</given-names></name><etal/></person-group><article-title>Oxidative stress and psoriasis: the effect of antitumour necrosis factor-&#x003b1; inhibitor treatment</article-title><source>Br. J. Dermatol.</source><year>2013</year><volume>168</volume><fpage>984</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1111/bjd.12144</pub-id><pub-id pub-id-type="pmid">23614561</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Compound glycyrrhizin plus conventional therapy for psoriasis vulgaris: a systematic review and meta-analysis of randomized controlled trials</article-title><source>Curr. Med. Res. Opin.</source><year>2017</year><volume>33</volume><fpage>279</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1080/03007995.2016.1254605</pub-id><pub-id pub-id-type="pmid">27786567</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van-de-Kerkhof</surname><given-names>PC</given-names></name></person-group><article-title>The Psoriasis Area and Severity Index and alternative approaches for the assessment of severity: persisting areas of confusion</article-title><source>Br. J. Dermatol.</source><year>1997</year><volume>137</volume><fpage>661</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.1997.tb03819.x</pub-id><pub-id pub-id-type="pmid">9390363</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlin</surname><given-names>CS</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name><name><surname>Krueger</surname><given-names>JG</given-names></name><name><surname>Menter</surname><given-names>A</given-names></name><name><surname>Krueger</surname><given-names>GG</given-names></name></person-group><article-title>A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis</article-title><source>J. Am. Acad. Dermatol.</source><year>2004</year><volume>50</volume><fpage>859</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2003.09.014</pub-id><pub-id pub-id-type="pmid">15153885</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szepietowski</surname><given-names>JC</given-names></name><name><surname>Reich</surname><given-names>A</given-names></name><name><surname>Wi&#x0015b;nicka</surname><given-names>B</given-names></name></person-group><article-title>Itching in patients suffering from psoriasis</article-title><source>Acta. Dermatovenerol. Croat.</source><year>2002</year><volume>10</volume><fpage>221</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">12588672</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haldane</surname><given-names>JB</given-names></name></person-group><article-title>The estimation and significance of the logarithm of a ratio of frequencies</article-title><source>Ann. Hum. Genet.</source><year>1956</year><volume>20</volume><fpage>309</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1111/j.1469-1809.1955.tb01285.x</pub-id><pub-id pub-id-type="pmid">13314400</pub-id></element-citation></ref></ref-list></back></article>